Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
Zak, M., Mendonca, R., Balazs, M., Barrett, K., Bergeron, P., Blair, W.S., Chang, C., Deshmukh, G., Devoss, J., Dragovich, P.S., Eigenbrot, C., Ghilardi, N., Gibbons, P., Gradl, S., Hamman, C., Hanan, E.J., Harstad, E., Hewitt, P.R., Hurley, C.A., Jin, T., Johnson, A., Johnson, T., Kenny, J.R., Koehler, M.F., Bir Kohli, P., Kulagowski, J.J., Labadie, S., Liao, J., Liimatta, M., Lin, Z., Lupardus, P.J., Maxey, R.J., Murray, J.M., Pulk, R., Rodriguez, M., Savage, S., Shia, S., Steffek, M., Ubhayakar, S., Ultsch, M., van Abbema, A., Ward, S.I., Xiao, L., Xiao, Y.
J.Med.Chem.
